FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943342119> ?p ?o ?g. }

• W2943342119 endingPage "907" @default.
• W2943342119 startingPage "899" @default.
• W2943342119 abstract "To evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).This was a multi-centre, randomised, double-blind, parallel-group, placebo-controlled phase 3 study in Japan. Patients with RA aged ≥20 years receiving csDMARDs were randomly assigned (1:1:1) to denosumab 60 mg every 3 months (Q3M), denosumab 60 mg every 6 months (Q6M) or placebo. The change in the modified total Sharp score (mTSS) and effect on bone mineral density (BMD) at 12 months was evaluated.In total, 654 patients received the trial drugs. Denosumab groups showed significantly less progression of joint destruction. The mean changes in the mTSS at 12 months were 1.49 (95% CI 0.99 to 1.99) in the placebo group, 0.99 (95% CI 0.49 to 1.49) in the Q6M group (p=0.0235) and 0.72 (95% CI 0.41 to 1.03) in the Q3M group (p=0.0055). The mean changes in bone erosion score were 0.98 (95% CI 0.65 to 1.31) in the placebo group, 0.51 (95% CI 0.22 to 0.80) in the Q6M group (p=0.0104) and 0.22 (95% CI 0.09 to 0.34) in the Q3M group (p=0.0001). No significant between-group difference was observed in the joint space narrowing score. The per cent change in lumbar spine (L1-L4) BMD in the placebo, Q6M and Q3M groups were -1.03%, 3.99% (p<0.0001) and 4.88% (p<0.0001). No major differences were observed among safety profiles.Denosumab inhibits the progression of joint destruction, increases BMD and is well tolerated in patients with RA taking csDMARD." @default.
• W2943342119 created "2019-05-09" @default.
• W2943342119 creator A5015953107 @default.
• W2943342119 creator A5042012204 @default.
• W2943342119 creator A5048761427 @default.
• W2943342119 creator A5053953126 @default.
• W2943342119 creator A5055584432 @default.
• W2943342119 creator A5063192431 @default.
• W2943342119 creator A5081469161 @default.
• W2943342119 creator A5083314956 @default.
• W2943342119 creator A5086531834 @default.
• W2943342119 creator A5089158758 @default.
• W2943342119 date "2019-04-29" @default.
• W2943342119 modified "2023-10-17" @default.
• W2943342119 title "Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial" @default.
• W2943342119 cites W1492940207 @default.
• W2943342119 cites W1867131794 @default.
• W2943342119 cites W1968857219 @default.
• W2943342119 cites W1983510723 @default.
• W2943342119 cites W1985004174 @default.
• W2943342119 cites W1985645291 @default.
• W2943342119 cites W1997823019 @default.
• W2943342119 cites W2051196478 @default.
• W2943342119 cites W2058858133 @default.
• W2943342119 cites W2066357843 @default.
• W2943342119 cites W2081734937 @default.
• W2943342119 cites W2086103128 @default.
• W2943342119 cites W2100025622 @default.
• W2943342119 cites W2113131907 @default.
• W2943342119 cites W2119076783 @default.
• W2943342119 cites W2119249533 @default.
• W2943342119 cites W2128952811 @default.
• W2943342119 cites W2129969349 @default.
• W2943342119 cites W2131382747 @default.
• W2943342119 cites W2132608084 @default.
• W2943342119 cites W2139996507 @default.
• W2943342119 cites W2152348310 @default.
• W2943342119 cites W2159106700 @default.
• W2943342119 cites W2171133944 @default.
• W2943342119 cites W2179986300 @default.
• W2943342119 cites W2262742107 @default.
• W2943342119 cites W2414767221 @default.
• W2943342119 cites W2522143920 @default.
• W2943342119 cites W2543720021 @default.
• W2943342119 cites W2545273878 @default.
• W2943342119 cites W2622000437 @default.
• W2943342119 cites W2623617647 @default.
• W2943342119 cites W2742684263 @default.
• W2943342119 cites W4211111012 @default.
• W2943342119 doi "https://doi.org/10.1136/annrheumdis-2018-214827" @default.
• W2943342119 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6585575" @default.
• W2943342119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31036625" @default.
• W2943342119 hasPublicationYear "2019" @default.
• W2943342119 type Work @default.
• W2943342119 sameAs 2943342119 @default.
• W2943342119 citedByCount "97" @default.
• W2943342119 countsByYear W29433421192019 @default.
• W2943342119 countsByYear W29433421192020 @default.
• W2943342119 countsByYear W29433421192021 @default.
• W2943342119 countsByYear W29433421192022 @default.
• W2943342119 countsByYear W29433421192023 @default.
• W2943342119 crossrefType "journal-article" @default.
• W2943342119 hasAuthorship W2943342119A5015953107 @default.
• W2943342119 hasAuthorship W2943342119A5042012204 @default.
• W2943342119 hasAuthorship W2943342119A5048761427 @default.
• W2943342119 hasAuthorship W2943342119A5053953126 @default.
• W2943342119 hasAuthorship W2943342119A5055584432 @default.
• W2943342119 hasAuthorship W2943342119A5063192431 @default.
• W2943342119 hasAuthorship W2943342119A5081469161 @default.
• W2943342119 hasAuthorship W2943342119A5083314956 @default.
• W2943342119 hasAuthorship W2943342119A5086531834 @default.
• W2943342119 hasAuthorship W2943342119A5089158758 @default.
• W2943342119 hasBestOaLocation W29433421191 @default.
• W2943342119 hasConcept C126322002 @default.
• W2943342119 hasConcept C141071460 @default.
• W2943342119 hasConcept C142724271 @default.
• W2943342119 hasConcept C204787440 @default.
• W2943342119 hasConcept C27081682 @default.
• W2943342119 hasConcept C2776286101 @default.
• W2943342119 hasConcept C2776541429 @default.
• W2943342119 hasConcept C2776886416 @default.
• W2943342119 hasConcept C2777077863 @default.
• W2943342119 hasConcept C2777575956 @default.
• W2943342119 hasConcept C71924100 @default.
• W2943342119 hasConcept C90924648 @default.
• W2943342119 hasConceptScore W2943342119C126322002 @default.
• W2943342119 hasConceptScore W2943342119C141071460 @default.
• W2943342119 hasConceptScore W2943342119C142724271 @default.
• W2943342119 hasConceptScore W2943342119C204787440 @default.
• W2943342119 hasConceptScore W2943342119C27081682 @default.
• W2943342119 hasConceptScore W2943342119C2776286101 @default.
• W2943342119 hasConceptScore W2943342119C2776541429 @default.
• W2943342119 hasConceptScore W2943342119C2776886416 @default.
• W2943342119 hasConceptScore W2943342119C2777077863 @default.
• W2943342119 hasConceptScore W2943342119C2777575956 @default.
• W2943342119 hasConceptScore W2943342119C71924100 @default.
• W2943342119 hasConceptScore W2943342119C90924648 @default.
• W2943342119 hasFunder F4320321625 @default.

• next